Nuveen Asset Management, LLC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 118 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.77 and the average weighting 0.1%.

Quarter-by-quarter ownership
Nuveen Asset Management, LLC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2024$27,781,480
+108.7%
4,495,385
+71.6%
0.01%
+100.0%
Q1 2024$13,308,893
-35.9%
2,619,861
-24.4%
0.00%
-42.9%
Q4 2023$20,767,114
+14.0%
3,466,964
+34.7%
0.01%
+16.7%
Q3 2023$18,219,248
+160.0%
2,573,340
+158.5%
0.01%
+200.0%
Q2 2023$7,008,201
+105429.3%
995,483
+25.0%
0.00%0.0%
Q1 2023$6,641
-64.0%
796,299
-50.4%
0.00%
-71.4%
Q4 2022$18,433
-99.9%
1,605,694
-15.6%
0.01%
-30.0%
Q3 2022$23,975,000
+17.7%
1,902,821
-1.2%
0.01%
+25.0%
Q2 2022$20,375,000
-47.5%
1,925,834
-21.6%
0.01%
-38.5%
Q1 2022$38,775,000
+18.6%
2,457,215
+4.1%
0.01%
+30.0%
Q4 2021$32,698,000
-6.3%
2,360,925
-2.8%
0.01%
-9.1%
Q3 2021$34,914,000
-13.9%
2,429,686
-5.3%
0.01%
-8.3%
Q2 2021$40,559,000
+59.2%
2,565,420
+2.4%
0.01%
+50.0%
Q1 2021$25,469,000
+117.4%
2,504,355
+59.3%
0.01%
+100.0%
Q4 2020$11,715,000
+109.7%
1,572,514
-3.3%
0.00%
+100.0%
Q3 2020$5,587,000
-30.5%
1,626,607
-3.6%
0.00%
-33.3%
Q2 2020$8,037,000
+125.6%
1,686,808
-5.3%
0.00%
+50.0%
Q1 2020$3,562,000
-3.4%
1,781,249
+66.7%
0.00%
+100.0%
Q4 2019$3,687,000
+56.4%
1,068,498
+29.8%
0.00%0.0%
Q3 2019$2,357,000
-24.0%
822,882
+0.6%
0.00%0.0%
Q2 2019$3,101,000818,2330.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q2 2019
NameSharesValueWeighting ↓
VHCP Management II, LLC 6,071,142$50,998,00020.86%
RTW INVESTMENTS, LP 3,458,120$29,048,0007.65%
ISZO CAPITAL MANAGEMENT LP 307,366$2,582,0004.49%
DAFNA Capital Management LLC 541,128$4,545,0003.84%
RA Capital Management 3,489,795$29,314,0003.60%
EMORY UNIVERSITY 375,348$3,153,0002.98%
Ghost Tree Capital, LLC 1,500,000$12,600,0002.35%
ACUTA CAPITAL PARTNERS, LLC 920,310$7,731,0001.83%
Avoro Capital Advisors LLC 1,603,001$13,465,0001.72%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,085,236$25,916,0001.00%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders